Biosimilar Development News
-
The Cigna Group Raises Long-Term Growth Target, And Launches New Innovative Solutions At 2024 Investor Day
3/7/2024
Today, global health company The Cigna Group (NYSE:CI), will outline its growth and innovation strategies at its 2024 Investor Day. In addition, the company is raising its long-term average annual adjusted EPS1 growth target to 10%-14% and is reaffirming its 2024 adjusted EPS1 guidance of at least $28.25.
-
Sandoz Receives FDA Approval For First And Only Denosumab Biosimilars
3/5/2024
Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) approved Wyost® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz), the first and only FDA-approved denosumab biosimilars, to treat all indications of the reference medicines.
-
WEZLANA™ (Ustekinumab), A Biosimilar To Stelara®, Now Available In Canada For Certain Chronic Inflammatory Diseases
3/4/2024
Amgen Canada today announced that WEZLANA (ustekinumab injection) and WEZLANA I.V. (ustekinumab for injection, solution for intravenous infusion), a biosimilar to STELARA, is now available in Canada.
-
Sandoz Acquires CIMERLI® Business From Coherus, Further Building Biosimilar And Ophthalmology Leadership In US Market
3/4/2024
Sandoz, the global leader in generic and biosimilar medicines, has completed the acquisition of the US biosimilar CIMERLI®* (ranibizumab-eqrn) from Coherus BioSciences, Inc, ahead of anticipated timelines.
-
Henlius Adalimumab Biosimilar Received sNDA Acceptance Notification From The NMPA
2/29/2024
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the supplemental new drug applications (sNDAs) of its adalimumab biosimilar HANDAYUAN for the treatment of polyarticular juvenile idiopathic arthritis,pediatric plaque psoriasis and other indications have been accepted by the National Medical Products Administration (NMPA),bringing new hope to pediatric patients and their families.
-
CGPA And Biosimilars Canada Statement On Proposed Pharmacare Legislation
2/29/2024
The following is a statement from Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) and Biosimilars Canada, in response to the federal government’s introduction of proposed pharmacare legislation:
-
Biocon Biologics Secures US Market Entry Date For Bmab 1200, A Proposed Biosimilar To Stelara®
2/29/2024
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the Company has signed a settlement and license agreement with Janssen Biotech Inc., and Johnson & Johnson (collectively known as Janssen) that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara®, in the United States of America.
-
Cardinal Health Annual Research Report Examines Milestone Year In Biosimilars
2/29/2024
Today, Cardinal Health (NYSE: CAH) released its 2024 Biosimilars Report: insights on a pivotal year of evolution and expansion, an analysis of key recent economic, competitive, legislative and societal developments in biosimilars.
-
Alvotech And Teva Announce U.S. Approval Of SIMLANDI® (adalimumab-ryvk) Injection, The First Interchangeable High-Concentration, Citrate-Free Biosimilar To Humira®
2/23/2024
Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis.
-
Mabwell Publishes The Phase III Study Results On Its Denosumab Biosimilar (MW032) In The Journal JAMA Oncology
2/23/2024
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, recently published the phase III study results of denosumab biosimilar (MW032) online in the international top journal of JAMA Oncology.